SCHEMBL25375720

SCHEMBL25375720

COc1cccc(C#N)c1NC(=O)NC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 1/20 0.52
TP53 P04637 1/20 0.52
RAB9A P51151 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
IMPDH2 P12268 2/20 0.43
LPAR1 Q92633 1/20 0.41
ATM Q13315 1/20 0.40
MEN1 O00255 2/20 0.40
MAPK1 P28482 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 4/20 0.39
LRRK2 Q5S007 1/20 0.39
PDGFRB P09619 1/20 0.38
FGFR1 P11362 1/20 0.38
SRC P12931 1/20 0.38
PDGFRA P16234 1/20 0.38
IMPDH1 P20839 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22979105 0.81 IMPDH2 (0.48) ALDH1A1SMN1; SMN2NPC1RAB9AIMPDH2
SCHEMBL25373430 0.81 MAPK1 (0.55) ALDH1A1SMN1; SMN2KDM4ENPC1TP53
SCHEMBL1620743 0.78 RAB9A (0.60) SMN1; SMN2NPC1RAB9AATMMEN1
SCHEMBL22987946 0.76 TSHR (0.53) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL30542576 0.75 KMT2A (0.48) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3854860 0.73 KCNK3 (0.46) ALDH1A1SMN1; SMN2KDM4ENPC1MEN1
SCHEMBL15784988 0.73 LMNA (0.46) ALDH1A1SMN1; SMN2NPSR1LPAR1ATM
SCHEMBL25374182 0.73 GAA (0.56) ALDH1A1RAB9ANPSR1MAPK1KMT2A
SCHEMBL28834851 0.72 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KDM4ENPC1TP53
SCHEMBL12631706 0.72 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171447-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF MERCK SHARP & DOHME LLC (US) 2025-05-29 US disclosed
EP-4479056-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF Merck Sharp & Dohme LLC (US) 2024-12-25 EP disclosed
WO-2023158626-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171447-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF ADORA2A, ADORA2B, ADORA1 ALDH1A1 483/4885SMN1; SMN2 1707/4885KDM4E 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.